{
    "clinical_study": {
        "@rank": "161714", 
        "arm_group": [
            {
                "arm_group_label": "1", 
                "arm_group_type": "Experimental", 
                "description": "75mg per day (in 3 doses) Talampanel for 22 days"
            }, 
            {
                "arm_group_label": "2", 
                "arm_group_type": "Placebo Comparator", 
                "description": "3 doses a day for 22 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this research study is to test the safety and effectiveness of the study\n      drug, Talampanel, when used to treat patients with involuntary movements known as\n      dyskinesias, as a result of treatment to Parkinson's disease.\n\n      It is not clear why people with Parkinson's disease develop involuntary movements\n      (dyskinesias) but studies show that blocking receptors in the brain for a chemical called\n      glutamate decreases these movements.  Talampanel is a drug which blocks these receptors."
        }, 
        "brief_title": "Effects of Talampanel on Patients With Advanced Parkinson's Disease", 
        "completion_date": {
            "#text": "February 2007", 
            "@type": "Actual"
        }, 
        "condition": [
            "Dyskinesias", 
            "Parkinson Disease", 
            "Movement Disorders"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dyskinesias", 
                "Movement Disorders", 
                "Parkinson Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Troublesome on-period dyskinesias as defined by a Unified Parkinson's Disease Rating\n             Scale (UPDRS) dyskinesia sub-score   >25% of Duration of dyskinesia during waking\n             hours and 33 must have moderate disability\n\n          -  Lang-Fahn dyskinesia rating score more than 2 for at least two of the 5 tasks\n\n          -  Must have Dyskinesia on average 25% of waking hours/day based on Patient Diaries\n\n          -  Have been diagnosed with Parkinson's disease > 5 years at Screening\n\n        Exclusion Criteria:\n\n          -  Previous surgical therapies for PD\n\n          -  Isolated or predominantly diphasic dyskinesias\n\n          -  Moderate Dementia\n\n          -  On disallowed concomitant medications including CYP3A4 inhibitors and inducers,\n             amantadine, etc."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 8, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00036296", 
            "org_study_id": "IXL-202-18-189"
        }, 
        "intervention": {
            "arm_group_label": [
                "1", 
                "2"
            ], 
            "description": "75mg per day divided into 3 doses for 22 days", 
            "intervention_name": "talampanel", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Involuntary Movements", 
            "Abnormal Movements", 
            "Advanced Parkinson's disease", 
            "Levodopa induced dyskinesia"
        ], 
        "lastchanged_date": "April 11, 2011", 
        "number_of_arms": "2", 
        "official_title": "Effects of Talampanel on Patients With Advanced Parkinson's Disease Who Have Been on Sinemet for More Than 5 Years and Have Dyskinesia (Abnormal Involuntary Movements)", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "February 2007", 
            "@type": "Actual"
        }, 
        "removed_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00036296"
        }, 
        "responsible_party": {
            "name_title": "Rivka Kreitman, Ph.D., Vice President, Innovative Research and Development", 
            "organization": "Teva Neuroscience"
        }, 
        "source": "Teva Pharmaceutical Industries", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Teva Pharmaceutical Industries", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2006", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2009"
    }, 
    "geocoordinates": {}
}